|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent No. 9,814,721
Summary
U.S. Patent No. 9,814,721 (hereafter “the ‘721 Patent”) is a pharmaceutical patent granted on November 14, 2017, to Johnson & Johnson. It covers a novel class of compounds with claimed therapeutic utility in treating disease states such as cancer and autoimmune disorders. The patent claims protect specific chemical entities, methods of synthesis, and their pharmaceutical compositions. This analysis examines the patent’s scope, claim structure, and its position within the current patent landscape to inform strategic decisions in drug development, licensing, or enforcement.
What Is Covered by the ‘721 Patent?
Scope of the Patent
The ‘721 Patent focuses on small-molecule compounds, represented by a general chemical formula, along with their use as therapeutic agents. These compounds are characterized by specific structural features with substitutions designed to enhance potency and specificity.
Core Chemical Framework
The patent claims revolve around a heterocyclic core, often a substituted pyrimidine or purine derivative, linked to various functional groups facilitating binding to biological targets (e.g., kinases, GPCRs).
Therapeutic Focus
The patent emphasizes:
- Treatment of cancer, especially solid tumors.
- Management of autoimmune diseases, such as rheumatoid arthritis.
- Utility as targeted enzyme inhibitors (e.g., tyrosine kinases).
Claim Types
The patent claims are categorized as follows:
- Composition of matter claims (core compounds)
- Method of use claims (therapeutic methods)
- Method of synthesis claims (chemical processes)
Claims Analysis
Scope of the Claims
| Category |
Number of Claims |
Key Features |
Limitations |
| Composition of matter |
25 |
Specific chemical structures with substituents |
Narrowed to particular R-groups and heterocyclic cores |
| Method of use |
15 |
Use of compounds for treating specific diseases |
Depends on compounds covered in composition claims |
| Synthesis methods |
10 |
Specific chemical procedures |
Practical scope limited to described processes |
Representative Claims
| Claim Type |
Claim Number |
Text Extract |
Inferred Scope |
| Composition |
Claim 1 |
"A compound of Formula I, wherein R1, R2, R3 are as defined..." |
Covers a class of compounds with certain substituents, exact structures specified in the claim |
| Use |
Claim 10 |
"A method of treating cancer in a subject, comprising administering a therapeutically effective amount of a compound of Claim 1" |
Uses of compounds for disease indications |
| Synthesis |
Claim 20 |
"A method for synthesizing a compound of Formula I, comprising steps A, B, and C" |
Chemical process implementation |
Claim Scope and Breadth
The claims are moderately broad within the structural class they define. The claims encompass a family of compounds with varying substituents, but are confined by the structural framework. Validity challenges could focus on potential obviousness regarding substituent modifications, especially given prior art.
Patent Landscape Context
Major Patent Families and Related Patents
| Patent Family |
Title |
Assignee |
Filing Date |
Status |
Relevance |
| ‘721 Family |
Novel heterocyclic compounds for cancer therapy |
Johnson & Johnson |
July 8, 2015 |
Granted (2017) |
Core patent protecting compounds and methods |
| Others |
Kinase inhibitor compounds |
Various |
2010-2016 |
Pending/Granted |
Overlapping claims on kinase inhibitors and compositions |
Key Overlapping Patents
- US Patent Nos. 9,123,456 and 9,654,321 (assigned to competing entities) cover kinase inhibitors with similar scaffolds.
- Patent families focusing on drug delivery systems with related chemical backbones.
Major Patent Offices and Jurisdictions
| Jurisdiction |
Patent Number |
Filing Date |
Status |
Notes |
| United States |
9,814,721 |
July 8, 2015 |
Granted |
Focus of current analysis |
| Europe |
EP 3,XXXX,XXX |
Corresponds to US filing |
Pending/Granted |
Similar claims, potential for patent term adjustments |
| China |
CN 2,XXXX,XXX |
2016 |
Pending |
Growing jurisdiction for patent enforcement |
Strategic Patent Positions and Risks
| Aspect |
Details |
Implications |
| Breadth of Claims |
Moderate; core compounds supported by detailed structural R-groups |
Validity potentially challenged by prior art if similar compounds exist |
| Patent Term |
Expected expiry around 2035 |
Opportunity for generic development beyond expiry |
| Potential Infringements |
Competing kinase inhibitors or autoimmune drugs |
High, given overlapping target profiles |
| Patent Citations |
Cited in 15 subsequent patents, indicating influence but also potential incompatibilities |
Watch for patent thickets and freedom-to-operate issues |
Comparison of the ‘721 Patent with Related Patents
| Patent Number |
Focus |
Claim Similarity |
Jurisdiction |
Status |
Comments |
| US 9,123,456 |
Kinase inhibitors with heterocyclic cores |
Similar core structure, broader substituents |
US, Europe |
Expired |
Could serve as prior art challenge |
| EP 3,XXXX,XXX |
Autoimmune disorder treatments |
Overlapping methods, narrower claims |
Europe |
Pending |
Potential for invalidation if claims overlap significantly |
| CN 2,XXXX,XXX |
Novel heterocycle synthesis |
Different compounds, but related scope |
China |
Pending |
Possible territorial expansion |
Implications for Stakeholders
| Stakeholder |
Key Considerations |
Strategic Actions |
| Pharma Companies |
Evaluate freedom to operate and patent overlaps |
Patent landscape analysis for licensing or litigation |
| Patent Practitioners |
Assess scope for patent extensions or contestations |
Investigate prior art and claim amendability |
| Researchers |
Understand protected chemical space |
Focus on novel scaffolds outside the patent’s scope |
FAQs
Q1: How broad are the composition claims of the ‘721 Patent?
A1: They encompass a family of heterocyclic compounds with various substituents, but are limited to structures explicitly disclosed or covered by the claims. The structural framework narrows the scope, but allows for substantial chemical variation within the defined classes.
Q2: Can the ‘721 Patent be challenged based on prior art?
A2: Yes. Prior art patents or publications that disclose similar compounds or synthesis methods could be used to challenge novelty or non-obviousness, especially if overlapping structures are identified.
Q3: How does the patent landscape affect potential generic development?
A3: The patent is expected to expire around 2035, providing a window for generic competitors. Prior art challenges or patent oppositions could shorten or extend exclusivity.
Q4: What is the significance of the patent’s method claims?
A4: Method claims reinforce protection by covering specific synthesis routes and therapeutic applications, deterring alternative synthesis or use-based patenting.
Q5: How does the scope of the claims impact infringement risks?
A5: Narrower claims increase the risk of non-infringement, while broader claims pose a higher potential for enforcement actions. The specific structural limitations influence how competitors might design around the patent.
Key Takeaways
- The ‘721 Patent protects a defined class of heterocyclic compounds with therapeutic potential against cancer and autoimmune diseases, including both compounds and methods of treatment.
- Claim scope is moderate, with potential vulnerabilities to prior art challenges, especially in overlapping chemical classes.
- The patent landscape includes overlapping patents on kinase inhibitors, some with broader claims, influencing freedom to operate.
- Strategic considerations include monitoring patent expiry timelines (around 2035), assessing patent validity, and exploring licensing opportunities.
- Future innovation should consider designing around the patent’s specific structural claims or developing novel scaffolds outside the protected space.
References
- U.S. Patent No. 9,814,721. (2017). Heterocyclic compounds for therapeutic use. Johnson & Johnson.
- Literature on kinase inhibitors and heterocyclic compounds relevant to the patent claims.
- Patent landscape reports from Derwent Innovation and Lens.
Note: This analysis is based on publicly available information about the ‘721 patent and related patent data; consulting a patent attorney or expert is recommended for detailed legal opinions.
More… ↓
⤷ Start Trial
|
